CareLit Fachartikel
Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review
Mengyuan Yang, Liuhong Wang, Ying Yuan · Zeitschrift für Gastroenterologie · 2022 · Heft 12 · S. 1787-1791
Dokument
863586
CareLit-ID
Jahr
2022
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Abstract Background Chemotherapy is the first treatment option for local advanced or metastatic intrahepatic cholangiocarcinoma (ICC). However, after first-line chemotherapy, there is no standard second-line treatment or targeted agents for these patients. Case presentation Here we present an advanced ICC patient who has received radical resection and adjuvant chemotherapy (gemcitabine + cisplatin). But the no evidence of disease (NED) was maintained for only 6 months after the end of chemotherapy. He then received palliative surgery, radiotherapy and systemic chemotherapy (Tegafur+Oxaliplatin (SOX) and Nab-Pacl…
Schlagworte
Vemurafenib
intrahepatisches Cholangiokarzinom
BRAF
Fallbericht
Übersicht
Intrahepatic Cholangiocarcinoma
Case report
Review
Zeitschrift für Gastroenterologie
